N/A N=56 Dyspareunia and Central Sensitization
Endometriosis · Central Sensitisation · Dyspareunia
Primary: Deep Dyspareunia Score — 3.08 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=67 Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
Endometriosis
Primary: Changes in the Sizes (mm) of Endometrioma, Deep Infiltrating Endometriosis (DIE) and Adenomyosis Lesions Summed by Type on Magnetic Resonance (MR) Images at Cycle 4…
N/A N=167 A Comparison of Narrow Band Imaging (NBI) and Standard White Light Laparoscopy to Detect Endometriosis
Endometriosis
Primary: Diagnostic Yield — 81; 25 participants
Phase 2 N=8 Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI
Endometriosis
Primary: Sensitivity of FES PET/MRI for Evaluating Endometriosis (Percentage of Positive Scans) — 67 percentage of positive scans — p=0.317
Phase 3 N=9 Novel Topical Therapies for the Treatment of Genital Pain
Female Genital Diseases
Primary: Reduction in Daily Genital Pain. — 2.4; 2.92; 3.42; 2.77 units on a scale — p=0.30
Phase 2 N=6 BGS649 Monotherapy in Moderate to Severe Endometriosis Patients
Endometriosis
Primary: Proportion of Patients Who Develop 2 or More Follicles With Diameter 16 mm or Larger — 2; 2; 0 Participants
Phase 2 N=30 Botulinum Toxin for Pelvic Pain in Women With Endometriosis
Endometriosis · Chronic Pelvic Pain · Pelvic Muscle Spasm
Primary: Number of Participants With Improvement in Pain — 11; 4 Participants
Phase 2 N=41 Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility
Recurrent Pregnancy Loss · Unexplained Infertility
Primary: Abnormal Microbiome Bacterial Sequencing
Phase 4 N=37 Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
Endometriosis · Infertility
Primary: Patients Who Responded to Controlled Ovarian Hyperstimulation — 7; 5; 3; 5 Participants
Phase 4 N=1 Ulipristal for Endometriosis-related Pelvic Pain
Endometriosis
Primary: Pelvic Pain — 3.5; 0.2; 3.9 units on a scale — p=<0.05
Phase 3 N=470 Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
Genital Warts
Primary: Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study — 0.191; 0.272; 0.103 participants
Phase 4 N=120 The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.
Infertility · Endometriosis
Primary: Number of Metaphase II Cells (MII) — 8.2; 8.2 MII cells
Phase 3 N=511 Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
Genital Warts
Primary: Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study. — 0.248; 0.294; 0.09 proportion of participants
Phase 2 N=76 Safety and Efficacy Study of MT-2990 in Women With Endometriosis
Endometrial Related Pain
Primary: Mean Change From Baseline to Week 16 in Nonmenstrual Pelvic Pain Using a Pain Scale Ranges From 0 (None) to 3 (Severe) — -0.28; -0.63 units on a scale
N/A N=35 Endometriosis Group Care
Endometriosis · Pelvic Pain
Primary: PROMIS Pain Interference SF 8a — -1.62 t-score
Phase 2 N=22 Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain
Endometriosis-related Pain
Primary: Changes in the Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Endometriosis-related Pain. — -0.66; -2.04; -2.14; -3.68 score on a scale
N/A N=204 Lymph Node Mapping in Patients With Endometrial Cancer
Endometrial Cancer
Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients
Phase 2 N=137 Efficacy and Safety Study of Elagolix in Women With Endometriosis
Endometriosis, Pain
Primary: Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Double-blind Treatment Phase — -0.24; -0.49; -0.37; -1.13 units on a scale — p=0.0262
N/A N=73 Laparoscopy vs. Robotic Surgery for Endometriosis (LAROSE): a Prospective Randomized Controlled Trial
Endometriosis
Primary: Operative Time — 106.6; 101.6 minutes — p=0.71
Phase 4 N=44 Resveratrol for Pain Due to Endometriosis
Endometriosis
Primary: Pain Scores Measured by VAS (Visual Analog Scale) at Day 42. — 3.2; 3.9 units on a scale — p=0.7
Phase 2 N=319 Bay98-7196, Dose Finding / POC Study
Endometriosis
Primary: Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days…
Phase 3 N=681 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain
Endometriosis
Primary: Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment — 23.7; 62.8; 29.1; 63.8 percentage…
Phase 3 N=149 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
Genital Psoriasis · Psoriasis
Primary: Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1) — 6; 55 Participants — p=<0.001
Phase 3 N=289 An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
Psoriasis
Primary: Percentage of Participants With a Modified sPGA-G Response at Week 16 — 19.5; 39.6 Percentage of participants — p=0.0003
Phase 3 N=504 Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain
Endometriosis
Primary: Percentage of Participants With a Response for Dysmenorrhea at Month 6 Based on Daily Assessment — 52.1; 78.2; 32.6; 64.4 percentage of participants
N/A N=15 Ultravision™ System to Facilitate Low Impact Laparoscopic Surgery for Endometriosis
Endometriosis
Primary: Procedure Completed Without Change in Intra-abdominal Pressure — 9 Participants
N/A N=120 Endometrial Injury for Unexplained Infertility
Infertility
Primary: Measurement of Uterine Artery Pulsatility Index — 2.40; 2.35 index — p=<0.05
Phase 3 N=872 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
Endometriosis
Primary: Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS) — 19.6; 46.4; 75.8 percentage of participants — p=< 0.001
Phase 4 N=60 Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial
HIV Infection · Vaginal Atrophy · Menopause
Primary: Change in Most Bothersome Symptom (MBS) of Vaginal Atrophy — 0; 1; 8; 4 Participants
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants